• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Intravenous Iron in Patients Undergoing Maintenance Hemodialysis

byConstance WuandAliya Ramjaun
November 5, 2018
in Chronic Disease, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Patients undergoing hemodialysis typically receive intravenous iron, despite a lack of established clinical efficacy. In this randomized controlled trial, investigators randomized 2141 patients undergoing hemodialysis to either high-dose iron sucrose, administrated proactively, or low-dose iron-sucrose, administered reactively to compare the safety and efficacy of these regimens in patients undergoing hemodialysis. The primary outcome examined was a composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death. Researchers found that the high-dose group required a lower median monthly dose of erythropoiesis-stimulating agent (median difference -7539 IU, 95% CI -9485 IU to -5582 IU), and that more rapid increases in hemoglobin level were observed over time for the high-dose group. The composite end point occurred in 30.5% of the high-dose group compared to 32.7% of the low-dose group (HR 0.88, 95% CI 0.76 to 1.03, p<0.001 for noninferiority, p=0.11 for superiority). In terms of individual outcomes, the rate of death was 22.5% in the high-dose group compared to 25.7% in the low-dose group (HR 0.84, 95% CI 0.71 to 1.00). The rate of hospitalization for heart failure was significantly lower in the high-dose group (HR 0.66, 95% CI 0.47 to 0.93). Rates of serious adverse events and infection were similar between the two groups.

Taken together, the results from this study indicate that high-dose proactive intravenous iron regimens are non-inferior to low-dose reactive intravenous iron regimens, with some improved outcomes and reduced need for erythropoiesis-stimulating agents. This study was limited in that it was open-label and did not examine quality of-life data. The safety of the high-dose regimen also needs to be studied long term.

Click to read the study in NEJM

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

Mazdutide significantly reduces weight in adults with overweight or obesity

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

Previous Post

Treatment of hypertension in low-risk patients not linked with improved outcomes

Next Post

E-cigarette users have greater odds of subsequent cigarette use

RelatedReports

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Pharma

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

July 11, 2025
Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

July 10, 2025
Age and number of islet autoantibodies associated with diabetes risk
Neurology

Inebilizumab improves outcome in patients generalized myasthenia gravis

July 10, 2025
Next Post
E-cigarette users have greater odds of subsequent cigarette use

E-cigarette users have greater odds of subsequent cigarette use

Increased risk of subsequent melanoma after first melanoma diagnosis

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

Combined MRI and NIH stroke scores may predict stroke prognosis

Quick Take: Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.